secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0000950103-25-003637
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA
--------------------------------------------------------------------------------

- FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.
- Pivotal study: 51% complete response (no surgeries), durable beyond 12 months (median 24 months).
- FY2024 net loss $126.2M ($0.47/share) vs $95.9M in 2023; revenue down 37% to $3.9M.
- Cash, equivalents, investments $97.9M; runway extended into 2026 beyond potential launch.
- Raised $87.5M in Dec 2024 from convertible preferred stock ($79M) and IP/royalty sale ($8.5M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/0000950103-25-003637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/dp226512_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-003637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer